Oral Biologics & Biosimilars Global Market Report 2025

Description

Biologics represent pharmaceuticals derived from living cells through highly intricate technology, whereas biosimilars are designed to function similarly to biologics but are not exact replicas. Within the oral biologics and biosimilar market, these drugs are administered orally to specifically target conditions such as Alzheimer's, multiple sclerosis, HIV/AIDS, and other serious ailments, as well as to address chronic diseases such as diabetes, arthritis, and cancer.

The primary therapy categories for oral biologics and biosimilars encompass lymphocyte modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors, immunostimulants, GPCR modulators, and others. Interleukin inhibitors serve as immunosuppressive medications that impede the function of interleukins. Various diseases treated include asthma, Crohn's disease, cancer, infectious disease, other autoimmune conditions, and more, employing molecular types such as vaccines, proteins and peptides, monoclonal antibodies, and other therapies. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

The oral biologics and biosimilars market research report is one of a series of new reports from The Business Research Company that provides oral biologics and biosimilars market statistics, including oral biologics and biosimilars industry global market size, regional shares, competitors with an oral biologics and biosimilars market share, detailed oral biologics and biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics and biosimilars industry. This oral biologics and biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral biologics & biosimilars market size has grown exponentially in recent years. It will grow from $7.04 billion in 2024 to $8.69 billion in 2025 at a compound annual growth rate (CAGR) of 23.5%. The growth in the historic period can be attributed to increased collaboration and partnerships between market players for better insights, increased need for immunology, increased demand due to cost-effective manufacturing process, aging population, government initiatives, and the ability to command high prices.

The oral biologics & biosimilars market size is expected to see exponential growth in the next few years. It will grow to $19.13 billion in 2029 at a compound annual growth rate (CAGR) of 21.8%. The growth in the forecast period can be attributed to robust research and development activities for the development of oral biologics, lean towards pills over injections, adoption of unhealthy lifestyles, technological advances, ease of use of oral biologics, increase in healthcare access, reimbursement of biologics, rise in biosimilars, and rising prevalence of chronic diseases. Major trends in the forecast period include investing in the oral biologics market to benefit from potentially strong profit margins, shifting to biologics, as the innovation rate is increasing in that field, developing microneedle injectors-based drugs to increase the bioavailability and eliminating side effects of subcutaneous route.

The growth of the oral biologics and biosimilar market is expected to be driven by the increasing prevalence of chronic diseases such as arthritis, asthma, and cancer. Unhealthy lifestyle factors, including long working hours, limited physical activity, and poor dietary habits, contribute to the rising incidence of chronic diseases. Biologics play a crucial role in treating these conditions, stimulating the immune system to combat diseases such as cancer. According to the United Nations, it is anticipated that chronic diseases will account for 70% of global fatalities by 2030. This surge in chronic diseases is a significant factor propelling the expansion of the biologics and biosimilar market.

The growth of the oral biologics and biosimilars market is also expected to be fueled by the increasing healthcare expenditure. Healthcare expenditure, measured in monetary terms, encompasses the total resources spent on healthcare goods and services within a specific period. The implications of healthcare expenditure impact the development, adoption, and accessibility of oral biologics and biosimilars. For instance, the Centers for Medicare & Medicaid Services project that the average National Health Expenditures (NHE) growth will exceed the average GDP growth, resulting in a rise in health spending as a share of GDP. The increasing healthcare expenditure, coupled with the high prevalence of chronic diseases, is expected to drive the growth of the oral biologics and biosimilars market.

The development of new insulin biosimilars is a prominent trend gaining traction in the oral biologics and biosimilar market. Major players in this market are investing in creating biosimilar versions of insulin to capture a larger market share. For example, in January 2023, Amgen, a US-based biotechnology firm, launched Amjevita, a biosimilar to Humira, reflecting advancements in the creation of insulin biosimilars. The goal is to reduce costs and enhance access to essential treatments. Amjevita offers a more affordable option for conditions such as arthritis and Crohn's disease, while insulin biosimilars aim to make diabetes treatments more accessible. These developments are fostering competition and driving innovation in the biologics sector. Amgen is dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics.

The role of technology is anticipated to continue driving market growth, particularly in the area of physiology simulation modeling. Advancements in this field contribute to greater efficiencies, such as Eli Lilly and Pfizer utilizing Amazon's Elastic Compute Cloud (EC2) platform for simulation models in early drug discovery. This approach significantly reduces the time required for simulations compared to traditional methods. The adoption of technology, especially in physiological simulation modeling, is expected to play a pivotal role in the further development of the oral biologics and biosimilar market.

In September 2023, Biocon Limited, an Indian pharmaceutical company, completed the acquisition of Eywa Pharma Inc. for $7.7 million. This strategic acquisition enhances Biocon's manufacturing infrastructure, ensuring a continuous supply and providing capacities for oral solid dosage products ahead of schedule. Eywa Pharma, Inc., a US-based pharmaceutical company specializing in oral biologics and biosimilars, aligns with Biocon's commitment to diversify and strengthen its market position.

Major companies operating in the oral biologics & biosimilars market include Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abello, Aimmune Therapeutics Inc., VIVUS Inc, Materia Medica Holding, VECTOR-MEDICA, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy's, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral biologics & biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oral biologics and biosimilar market consists of sales of receptor modulators, biological agents, and biosimilar lymphocytes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Biologics & Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral biologics & biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral biologics & biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral biologics & biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies
2) By Disease: Diabetes, Arthritis and Crohn's Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases
3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: T-Cell Modulators; B-Cell Modulators; Sphingosine-1-Phosphate Receptor Modulators
2) By Interleukin Inhibitors: IL-1 Inhibitors; IL-6 Inhibitors; IL-17 Inhibitors; IL-23 Inhibitors
3) By Tumor Necrosis Factor-Alpha Inhibitors: TNF-a Blockers; Monoclonal Antibodies Targeting TNF-a
4) By Immunostimulants: Cytokines; Immune Checkpoint Inhibitors; Adjuvants
5) By GPCR Modulators: Agonists; Antagonists; Biased Ligands
6) By Other Therapies: Cell-Based Therapies; Gene Therapies; Combination Therapies
Companies Mentioned: Merck & Co. Inc.; GlaxoSmithKline; Novo Nordisk; ALK-Abello; Aimmune Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25836

1. Executive Summary

2. Oral Biologics & Biosimilars Market Characteristics

3. Oral Biologics & Biosimilars Market Trends And Strategies

4. Oral Biologics & Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Oral Biologics & Biosimilars Growth Analysis And Strategic Analysis Framework

5.1. Global Oral Biologics & Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oral Biologics & Biosimilars Market Growth Rate Analysis
5.4. Global Oral Biologics & Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oral Biologics & Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oral Biologics & Biosimilars Total Addressable Market (TAM)

6. Oral Biologics & Biosimilars Market Segmentation

6.1. Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lymphocyte Modulators
Interleukin Inhibitors
Tumor Necrosis Factor-Alpha Inhibitors
Immunostimulants
GPCR Modulators
Other Tharpies
6.2. Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diabetes
Arthritis and Crohn's Disease
Cancer
Infectious Disease
Other Autoimmune Disease
Other Diseases
6.3. Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vaccines
Proteins and Peptides
Monoclonal Antibodies
Other Molecule Types
6.4. Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Lymphocyte Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
T-Cell Modulators
B-Cell Modulators
Sphingosine-1-Phosphate Receptor Modulators
6.6. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Interleukin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
IL-1 Inhibitors
IL-6 Inhibitors
IL-17 Inhibitors
IL-23 Inhibitors
6.7. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Tumor Necrosis Factor-Alpha Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
TNF-a Blockers
Monoclonal Antibodies Targeting TNF-a
6.8. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Immunostimulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cytokines
Immune Checkpoint Inhibitors
Adjuvants
6.9. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of GPCR Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Agonists
Antagonists
Biased Ligands
6.10. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Other Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cell-Based Therapies
Gene Therapies
Combination Therapies

7. Oral Biologics & Biosimilars Market Regional And Country Analysis

7.1. Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Biologics & Biosimilars Market

8.1. Asia-Pacific Oral Biologics & Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Biologics & Biosimilars Market

9.1. China Oral Biologics & Biosimilars Market Overview
9.2. China Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Biologics & Biosimilars Market

10.1. India Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Biologics & Biosimilars Market

11.1. Japan Oral Biologics & Biosimilars Market Overview
11.2. Japan Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Biologics & Biosimilars Market

12.1. Australia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Biologics & Biosimilars Market

13.1. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Biologics & Biosimilars Market

14.1. South Korea Oral Biologics & Biosimilars Market Overview
14.2. South Korea Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Biologics & Biosimilars Market

15.1. Western Europe Oral Biologics & Biosimilars Market Overview
15.2. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Biologics & Biosimilars Market

16.1. UK Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Biologics & Biosimilars Market

17.1. Germany Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Biologics & Biosimilars Market

18.1. France Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Biologics & Biosimilars Market

19.1. Italy Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Biologics & Biosimilars Market

20.1. Spain Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Biologics & Biosimilars Market

21.1. Eastern Europe Oral Biologics & Biosimilars Market Overview
21.2. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Biologics & Biosimilars Market

22.1. Russia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Biologics & Biosimilars Market

23.1. North America Oral Biologics & Biosimilars Market Overview
23.2. North America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Biologics & Biosimilars Market

24.1. USA Oral Biologics & Biosimilars Market Overview
24.2. USA Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Biologics & Biosimilars Market

25.1. Canada Oral Biologics & Biosimilars Market Overview
25.2. Canada Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Biologics & Biosimilars Market

26.1. South America Oral Biologics & Biosimilars Market Overview
26.2. South America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Biologics & Biosimilars Market

27.1. Brazil Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Biologics & Biosimilars Market

28.1. Middle East Oral Biologics & Biosimilars Market Overview
28.2. Middle East Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Biologics & Biosimilars Market

29.1. Africa Oral Biologics & Biosimilars Market Overview
29.2. Africa Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Biologics & Biosimilars Market Competitive Landscape And Company Profiles

30.1. Oral Biologics & Biosimilars Market Competitive Landscape
30.2. Oral Biologics & Biosimilars Market Company Profiles
- 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GlaxoSmithKline Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. ALK-Abello Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Aimmune Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Oral Biologics & Biosimilars Market Other Major And Innovative Companies

31.1. VIVUS Inc
31.2. Materia Medica Holding
31.3. VECTOR-MEDICA
31.4. Henlius
31.5. Innovent Biologics
31.6. Bio-Thera
31.7. Hisun Pharma
31.8. 3SBio
31.9. Beijing ShuangLu Pharmaceuticals
31.10. Qilu Pharmaceutical
31.11. Shanghai Fosun Pharmaceuticals
31.12. Biocon
31.13. Dr.Reddy's
31.14. Mylan
31.15. Kyowa Hakko Kirin

32. Global Oral Biologics & Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Biologics & Biosimilars Market

34. Recent Developments In The Oral Biologics & Biosimilars Market

35. Oral Biologics & Biosimilars Market High Potential Countries, Segments and Strategies

35.1 Oral Biologics & Biosimilars Market In 2029 - Countries Offering Most New Opportunities
35.2 Oral Biologics & Biosimilars Market In 2029 - Segments Offering Most New Opportunities
35.3 Oral Biologics & Biosimilars Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer